Ignite Creation Date:
2025-12-24 @ 5:38 PM
Ignite Modification Date:
2026-02-28 @ 11:20 AM
Study NCT ID:
NCT02363868
Status:
COMPLETED
Last Update Posted:
2015-07-07
First Post:
2015-02-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Sponsor:
Bristol-Myers Squibb
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CA180-568
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None